Shire Buys Rare Disease Biopharma Co. for $4.2B

Nov 11, 2013


Shire PLC will acquire Pennyslvania-based ViroPharma Inc., as part of a strategic move to strengthen rare disease portfolio.

It is being reported that several large companies, including France's Sanofi, were interested in ViroPharma.

ViroPharma's lead drug is Cinryze, a $350,000-a-year treatment for hereditary angioedema. Cinryze will complement Shire's Firazyr, an on-demand treatment for acute attacks of hereditary angioedema, by providing long-term prophylactic prevention.

The sale is part of a wave of large drugmakers slashing non-core activities in order to free up funds to boost new drug pipelines through aquisitions.

Read the Reuters press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments